Literature DB >> 21831600

Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis.

Clemente Garcia-Rizo1, Emilio Fernandez-Egea, Cristina Oliveira, Azucena Justicia, Eduard Parellada, Miguel Bernardo, Brian Kirkpatrick.   

Abstract

BACKGROUND: Previous studies have found increased prolactin concentrations in antipsychotic-naïve patients with schizophrenia. However, the roles of other hormones, and of potentially confounding variables such as gender and smoking, have not been considered.
METHODS: Blood from newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis (13 women and 20 men) and matched controls (12 women and 21 men) was assayed for prolactin, as well as three other hormones that impact prolactin concentrations: thyrotropin-stimulating hormone (TSH), ghrelin, and cortisol.
RESULTS: Patients had significantly higher prolactin concentrations: female patients had a mean [SD] of 37.1 ng/mL [24.9] vs. 13.5 ng/mL [7.2] for female control subjects (p=.001), while male patients had a mean of 15.3 ng/mL [9.5] vs. 7.6 ng/mL [2.2] for male control subjects (p=.006). Patients and control subjects did not differ on concentrations of TSH, ghrelin, or cortisol. The group differences could not be attributed to differences in age, gender, smoking, body mass index, ethnicity, or the socioeconomic status of the family of origin.
CONCLUSIONS: Increased prolactin concentrations in antipsychotic-naïve patients do not appear to be due to important confounding variables, or to the effects of elevated TSH, ghrelin, or cortisol.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831600      PMCID: PMC4185192          DOI: 10.1016/j.schres.2011.07.025

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  25 in total

1.  The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats.

Authors:  S Kapur; X Langlois; P Vinken; A A H P Megens; R De Coster; J S Andrews
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

2.  Antipsychotic drugs, menstrual regularity and osteoporosis risk.

Authors:  J H Zhang-Wong; M V Seeman
Journal:  Arch Womens Ment Health       Date:  2002-11       Impact factor: 3.633

3.  Systemic oxytocin induces a prolactin secretory rhythm via the pelvic nerve in ovariectomized rats.

Authors:  Cleyde V Helena; Ruth Cristancho-Gordo; Arturo E Gonzalez-Iglesias; Joël Tabak; Richard Bertram; Marc E Freeman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-06-15       Impact factor: 3.619

4.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

5.  The association of serum prolactin concentration with inflammatory biomarkers - cross-sectional findings from the population-based Study of Health in Pomerania.

Authors:  Nele Friedrich; Harald J Schneider; Christin Spielhagen; Marcello Ricardo Paulista Markus; Robin Haring; Hans J Grabe; Michael Buchfelder; Henri Wallaschofski; Matthias Nauck
Journal:  Clin Endocrinol (Oxf)       Date:  2011-10       Impact factor: 3.478

6.  Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.

Authors:  Fabrice Duval; Marie-Claude Mokrani; José Monreal; Paul Bailey; Marcelo Valdebenito; Marc-Antoine Crocq; Jean-Paul Macher
Journal:  Psychoneuroendocrinology       Date:  2003-07       Impact factor: 4.905

7.  Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia.

Authors:  V Peralta; M J Cuesta
Journal:  Psychiatry Res       Date:  1994-07       Impact factor: 3.222

Review 8.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.

Authors:  Anne T Harvey; David Flockhart; J Christopher Gorski; David J Greenblatt; Michael Burke; Steve Werder; Sheldon H Preskorn
Journal:  J Clin Pharmacol       Date:  2004-10       Impact factor: 3.126

10.  Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia.

Authors:  Salvador Sarró; Rosa M Dueñas; Nicolás Ramírez; Belén Arranz; Ramón Martínez; José M Sánchez; José M González; Laura Saló; Luisa Miralles; Luis San
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

View more
  16 in total

Review 1.  Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.

Authors:  Meritxell Tost; José Antonio Monreal; Antonio Armario; Juan David Barbero; Jesús Cobo; Clemente García-Rizo; Miquel Bioque; Judith Usall; Elena Huerta-Ramos; Virginia Soria; Javier Labad
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

2.  Progress in the study of negative symptoms.

Authors:  Brian Kirkpatrick
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

Review 3.  Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions.

Authors:  Tanya T Nguyen; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

4.  Screening for substance use disorders in first-episode psychosis: implications for readmission.

Authors:  Albert Batalla; Clemente Garcia-Rizo; Pere Castellví; Emili Fernandez-Egea; Murat Yücel; Eduard Parellada; Brian Kirkpatrick; Rocío Martin-Santos; Miguel Bernardo
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

Review 5.  Schizophrenia: a systemic disorder.

Authors:  Brian Kirkpatrick; Brian Miller; Clemente García-Rizo; Emilio Fernandez-Egea
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-07

Review 6.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 7.  Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.

Authors:  Benedicto Crespo-Facorro; Jose Maria Pelayo-Teran; Jacqueline Mayoral-van Son
Journal:  Neurol Ther       Date:  2016-08-23

8.  Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis.

Authors:  Itziar Montalvo; Alfonso Gutiérrez-Zotes; Marta Creus; Rosa Monseny; Laura Ortega; Joan Franch; Stephen M Lawrie; Rebecca M Reynolds; Elisabet Vilella; Javier Labad
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

Review 9.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27

Review 10.  Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity.

Authors:  C Gragnoli; G M Reeves; J Reazer; T T Postolache
Journal:  Transl Psychiatry       Date:  2016-04-19       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.